SCHEMBL18009089

SCHEMBL18009089

CCOC(=O)/C=C/C(=O)OCC1NC(=O)NC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 3/20 0.41
HTT P42858 2/20 0.41
TDP1 Q9NUW8 1/20 0.38
MAPK1 P28482 1/20 0.36
MAPT P10636 4/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
APOBEC3A P31941 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18007464 0.92 GAA (0.39) HCAR2SMN1; SMN2ALDH1A1HTTMEN1
SCHEMBL18009344 0.92 GAA (0.39) HCAR2SMN1; SMN2ALDH1A1HTTMEN1
SCHEMBL18007465 0.92 GAA (0.39) HCAR2SMN1; SMN2ALDH1A1HTTMEN1
SCHEMBL18009125 0.88 HCAR2 (0.39) HCAR2SMN1; SMN2ALDH1A1HTTMEN1
SCHEMBL18009123 0.88 HCAR2 (0.39) HCAR2SMN1; SMN2ALDH1A1HTTMEN1
SCHEMBL18009090 0.88 HCAR2 (0.39) HCAR2SMN1; SMN2ALDH1A1HTTMEN1
SCHEMBL17969458 0.88 HCAR2 (0.42) HCAR2SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL17966450 0.88 HCAR2 (0.42) HCAR2SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL18009095 0.84 HTT (0.34) HCAR2SMN1; SMN2ALDH1A1HTTCYP2C19
SCHEMBL18009093 0.84 HCAR2 (0.44) HCAR2SMN1; SMN2ALDH1A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630934-B2 Fumarate compounds, pharmaceutical compositions thereof, and methods of use Nguyen, Mark Quang (US) 2017-04-25 US disclosed
US-9630934-B2 Fumarate compounds, pharmaceutical compositions thereof, and methods of use Nguyen, Mark Quang (US) 2017-04-25 US disclosed
WO-2016127186-A1 FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE NGUYEN MARK QUANG (US) 2016-08-11 WO disclosed
US-20160229819-A1 FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE Nguyen, Mark Quang (US) 2016-08-11 US disclosed
US-20160229819-A1 FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE Nguyen, Mark Quang (US) 2016-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229819-A1 FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE FH, FPGS, APC HCAR2 290/4885SMN1; SMN2 79/4885ALDH1A1 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.